Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

NKTR shares climb to $9.54 amid investor optimism and Phase IIb REZOLVE-AD results; EPS forecasts up 10.5% in 30 days.

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...